Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)

datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorAcosta González, Juan Daniel
dc.contributor.authorVázquez Jiménez, Lourdes Carolina
dc.contributor.authorRodríguez Yánez, Tomás
dc.contributor.authorDaza Arnedo, Rodrigo
dc.contributor.authorOspina Lopera, Stephanie
dc.contributor.authorRico Fontalvo, Jorge
dc.date.accessioned2024-09-23T15:21:12Z
dc.date.available2024-09-23T15:21:12Z
dc.date.issued2024
dc.description.abstractLa diabetes mellitus postrasplante (DMPT) es una complicación que se encuentra de forma frecuente y se sucede al trasplante de órganos. Existen factores predisponentes a esta complicación, son varios y pueden estar presentes en el pretrasplante, peritrasplante o ya en el pos trasplante; dentro de estos, se resaltan las terapias inmunosupresoras asociadas. La importancia clínica de DMPT radica en su impacto para la enfermedad cardiovascular (ECV) y enfermedad renal crónica (ERC). En el presente artículo hacemos una revisión de las intervenciones tradicionales y las nuevas terapias para el manejo y tratamiento de la DMPT.spa
dc.description.abstractPost transplant diabetes mellitus (PTDM) is a frequent complication after organ transplantation. There are several predisposing factors for this complication, which may be present in the pre-transplant, peri-transplant, or already post-transplant; within these, associated immunosuppressive therapies will be highlighted. The clinical importance of DMPT lies in its impact on cardiovascular disease (CVD) and chronic kidney disease (CKD). In this article, we review traditional interventions and new therapies for managing and treating PTDM.eng
dc.format.mimetypepdf
dc.identifier.citationAcosta González J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Ospina Lopera S, Rico Fontalvo J. Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt). An. Fac. Cienc. Méd. (Asunción), Agosto - 2024; 57(2): 82-89 DOI: http://dx.doi.org/10.18004/anales/2024.057.02.82spa
dc.identifier.doihttp://dx.doi.org/10.18004/anales/2024.057.02.82
dc.identifier.issn1816-8949
dc.identifier.urihttps://hdl.handle.net/20.500.12442/15687
dc.identifier.urlhttp://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1816-89492024000200082&lng=es&nrm=iso&tlng=es
dc.language.isospa
dc.publisherUniversidad Nacional de Asunción. Editorial de la Facultad de Ciencias Médicas EFACIMspa
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subjectDiabetes Mellitusspa
dc.subjectTrasplantespa
dc.subjectInmunosupresiónspa
dc.subjectHiperglucemiaspa
dc.subjectDiabetes pos trasplantespa
dc.subject.keywordsTransplanteng
dc.subject.keywordsImmunosuppressioneng
dc.subject.keywordsHyperglycemiaeng
dc.subject.keywordsPost-transplant diabeteseng
dc.titleOpciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)spa
dc.title.translatedTherapeutic options in patients with post-diabetes mellitus transplanteng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesHecking M, Sharif A, Eller K, Jenssen T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl Int. 2021 Jan;34(1):27-48. doi: 10.1111/tri.13783. Epub 2020 Nov 28. PMID: 33135259; PMCID: PMC7839745. eng
dcterms.referencesMontero N, Oliveras L, Soler MJ, Cruzado JM. Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clin Kidney J. 2021 Jul 10;15(1):5-13. doi: 10.1093/ckj/sfab131. PMID: 35265335; PMCID: PMC8901587. eng
dcterms.referencesMalik RF, Jia Y, Mansour SG, Reese PP, Hall IE, Alasfar S, Doshi MD, Akalin E, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Thiessen Philbrook HR, Parikh CR. Post-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study. Kidney360. 2021 Jun 2;2(8):1296-1307. doi: 10.34067/KID.0000862021. PMID: 35369651; PMCID: PMC8676388. eng
dcterms.referencesHabibnia F, Oliaei F, Shirafkan H, Abbasi Firoozjah M, Rezaei Roshan M, Akbari R. Ten-year incidence of post-transplant Diabetes Mellitus in renal transplant patients. Diab Vasc Dis Res. 2022;19(6):14791641221137352. Doi: 10.1177/14791641221137352. eng
dcterms.referencesJenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. marzo de 2019;15(3):172-88. doi: 10.1038/s41574-018-0137-7. eng
dcterms.referencesRodríguez-Rodríguez AE, Porrini E, Hornum M, Donate-Correa J, Morales-Febles R, Khemlani Ramchand S, et al. Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update. Nephron. 2021;145(4):317-29. doi: 10.1159/000514288. eng
dcterms.referencesF V, S F, E S, L R, T J, Jm C, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506-14. doi: 10.1111/j.1600-6143.2007. 01749.x. eng
dcterms.referencesLawendy B, Srinathan S, Kotha S, Gomes C, Misra S, Yu J, et al. Systematic review and meta-analysis of post-transplant diabetes mellitus in liver transplant recipients. Clin Transplant. 2021;35(7): e14340. doi: 10.1111/ctr.14340. eng
dcterms.referencesMüller MM, Schwaiger E, Kurnikowski A, Haidinger M, Ristl R, Tura A, et al. Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity with Tacrolimus- Versus Belatacept-Based Immunosuppression. Am J Kidney Dis. 2021 ;77(3):462-464. doi: 10.1053/j.ajkd.2020.07.016. eng
dcterms.referencesDucloux D, Courivaud C. Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach. J Pers Med. 2022;12(1):116. doi: 10.3390/jpm12010116. eng
dcterms.referencesKuningas K, Driscoll J, Mair R, Smith H, Dutton M, Day E, et al. Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial. Transplantation. 2020 Jul;104(7):1491-1499. doi: 10.1097/TP.0000000000002969. eng
dcterms.referencesWilcox J, Waite C, Tomlinson L, Driscoll J, Karim A, Day E, et al. Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial. Trials. 2016;17(1):417. doi: 10.1186/s13063-016-1543-6. eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. octubre de 2020;98(4S): S1-115. doi: 10.1016/j.kint.2020.06.019. eng
dcterms.referencesde Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90. /doi.org/10.2337/dci22-0027. eng
dcterms.referencesLalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547-53. Diabetes Care. doi: 10.2337/dc17-2231. eng
dcterms.referencesAnderson S, Cotiguala L, Tischer S, Park JM, McMurry K. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. Ann Pharmacother. 2021;55(4):496-508. doi: 10.1177/1060028020951955. eng
dcterms.referencesMiyazaki R, Miyagi K. Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrol. 2022;23(1):168. 2022;23(1):168. doi: 10.1186/s12882-022-02793-9. eng
dcterms.referencesLim LM, Chang JM, Kuo HT. Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes. Biomedicines. 2023;11(2):470. doi: 10.3390/biomedicines11020470. eng
dcterms.referencesThiruvengadam S, Hutchison B, Lim W, Bennett K, Daniels G, Cusack N, et al. Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy. Diabetes Metab Syndr. 2019;13(3):1857-63. doi: 10.1016/j. dsx.2019.04.020. eng
dcterms.referencesSingh P, Taufeeq M, Pesavento TE, Washburn K, Walsh D, Meng S. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study. Diabetes Obes Metab. 2020;22(5):879-84. doi: 10.1111/dom.13964. eng
dcterms.referencesGembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, et al. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci. 2021;22(9):4824. doi: 10.3390/ijms22094824. eng
dcterms.referencesDaza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, Leal-Martínez V, Abuabara-Franco E, Raad-Sarabia M, et al. Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Med. 2021;3(6):1065-73. doi: 10.1016/j.xkme.2021.07.007. eng
dcterms.referencesStrøm Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29(4):926-33. 2014 doi: 10.1093/ndt/gft536. eng
dcterms.referencesRico Fontalvo JE, Vázquez Jiménez LC, Rodríguez Yánez T, Daza Arnedo R, Raad M, Montejo Hernandez JD, et al. Enfermedad renal diabética: puesta al día. Rev An Fac Cienc Médicas. 2022;55(3):86-98. doi.org/10.18004/anales/2022.055.03.86.spa
dcterms.referencesRico-Fontalvo J, Daza-Arnedo R, Cardona-Blanco MX, Leal-Martínez V, Abuabara-Franco E, Pajaro-Galvis N, et al. SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J Clin Nephrol. 2020;4(1):044-55. doi: 10.29328/journal.jcn.1001058 eng
dcterms.referencesAlKindi F, Chaaban A, AlHakim M, Hussain Q, Boobes Y. Review of efficacy and short term safety of sodium - glucose cotransporter 2 (SGLT2) inhibitors use in diabetic renal transplant recipients. Transplantation. 2020;104(S3): S384. doi: 10.1097/01. tp.0000700516.51604.6e eng
dcterms.referencesSridhar VS, Ambinathan JPN, Gillard P, Mathieu C, Cherney DZI, Lytvyn Y, et al. Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation. 1 de abril de 2022;106(4):734-48. doi: 10.1097/TP.0000000000003919. eng
dcterms.referencesKwon H, Son SH, Kim K, Jeong JH, Hwang EJ, Yoon CS, et al. Sodium/glucose cotransporter 2 inhibitors reduce microalbuminuria in diabetic renal transplant patients. Transplantation. 2020;104(S3): S430–S430. doi: 10.1097/01. tp.0000700792.22109. b0. eng
dcterms.referencesLim J-H, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation. 2022;106(9): e404–12. doi: 10.1097/TP.0000000000004228. eng
dcterms.referencesLin Y, Mok M, Harrison J, Battistella M, Farrell A, Leung M, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. Transplant Rev. 2023;37(1):100729. doi: 10.1016/j.trre.2022.100729. eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
PDF.pdf
Tamaño:
379.52 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones